Novel approaches to CMV after HCT: report from the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22–25 April 2017

摘要

Cytomegalovirus (CMV) infection is a potentially life-threatening complication after hematopoietic cell transplan-tation (HCT). The potential availability of novel preventive therapies was therefore an important topic duringEuropean Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2017.A member of the β-herpesvirus family, CMV is a ubiquitous pathogen that is usually acquired in childhood orearly adult life through contact with body fluids. After primary infection, the virus becomes latent and rarely causessymptoms in healthy individuals. However, in immunocompromised hosts, CMV infection can lead to invasivedisease in almost any tissue, and represents one of the most common and significant complications after allogeneicHCT.